PharmaVoice on longevity science picking up steam at Retro and Lysoway

Posted by patient_codes in Longevity & Anti-Aging - 1 points, 0 comments.

https://www.pharmavoice.com/news/longevity-science-pharma-aging-retro-lilly-glp1/821440

PharmaVoice has a piece on longevity biotech getting real traction in pharma this year. Retro Biosciences and Lysoway Therapeutics both pushed candidates into Phase 1, Retro with RTR242 and Lysoway with LW-1017, both going after neurodegeneration which honestly is the area I am most desperate to see something move in.

What I like here is that these are not some "longevity clinic" rebranding NAD drips, they are actual IND-stage programs with specific mechanisms and trial endpoints. That matters because the space is drowning in hype right now. Forbes ran a piece this quarter saying longevity biotech raised almost $3.7B in Q1 alone, up 56% year over year, and a lot of that money is chasing stuff that will never make it past a mouse model. So when I see Retro and Lysoway crossing into Phase 1 I pay attention.

My worry is the same as always though, neurodegeneration trials are brutal, endpoints get moved, effect sizes get watered down, and then everyone calls the whole field a bust. Anyone else watching these two programs specifically, or is your eye on something else in the longevity pipeline?

Community discussion - research and educational context only. Not medical advice.